TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, 'Astellas') will present 24-week results from the Phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women considered unsuitable for hormone therapy, in an oral presentation on November 30 at the 15th Congress of the European Society of Gynecology in Amsterdam, The Netherlands (Abstract #12497).

VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2

The study of more than 450 women considered unsuitable for hormone therapy met all primary and secondary endpoints at 24 weeks.

For the primary endpoint of mean change from baseline in the frequency of moderate to severe VMS, fezolinetant 45 mg demonstrated a statistically significant reduction of -1.93 (p

(C) 2023 Electronic News Publishing, source ENP Newswire